Background illustration for clinical trials search

Ovarian Cancer Clinical Trials

Browse 1,660 ovarian cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Registry Study for Radiation Therapy Outcomes

for
Neoplasms
Location: New York NY, Somerset NJ, Hampton VA, Baltimore MD,
Sponsor: Proton Collaborative Group

Sex: All

Age: 0+

Code: NCT01255748

Recruiting

Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses

for
Cancer
Location: Milwaukee WI
Sponsor: Medical College of Wisconsin

Sex: All

Age: 18+

Code: NCT05674825

Phase 1, Phase 2, Recruiting

Behaviour Change for Cancer Survivors Trial

for
Cancer, Exercise
Location: Toronto
Sponsor: University of Toronto

Sex: All

Age: 18+

Code: NCT06624930

Recruiting

Registry of Older Patients With Cancer

for
Chronic Myeloproliferative Disorders,
Location: Morehead City NC, New Bern NC, Greenville NC,
Sponsor: UNC Lineberger Comprehensive Cancer Center

Sex: All

Age: 65+

Code: NCT01137825

Recruiting

Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure

for
Cardiotoxicity, Pediatric Cancer, Heart Failure
Location: San Diego CA
Sponsor: Hari Narayan

Sex: All

Age: 13 - 39

Code: NCT04262830

Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

for
Cancer
Location: Columbus OH
Sponsor: Ohio State University Comprehensive Cancer Center

Sex: All

Age: 18+

Code: NCT02090530

Recruiting

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Providence RI, New Haven CT, Miami FL, Charleston SC,
Sponsor: Eikon Therapeutics

Sex: All

Age: 18 - 70+

Code: NCT06253130

Phase 1, Phase 2, Recruiting

Study of STP938 (Dencatistat) in Advanced Solid Tumours

for
Solid Tumor
Location: St. Petersburg FL, Dallas TX, San Antonio TX
Sponsor: Step Pharma, SAS

Sex: All

Age: 18+

Code: NCT06297525

Phase 1, Recruiting

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

for
Solid Tumor, Adult, Refractory Cancer,
Location: Boston MA, New Haven CT, New York NY, Fairfax VA,
Sponsor: GV20 Therapeutics

Sex: All

Age: 18+

Code: NCT05669430

Phase 1, Phase 2, Recruiting

ORB-021 In Patients With Advanced Solid Tumors

for
Advanced Solid Tumors Cancer
Location: Houston TX, Scottsdale AZ
Sponsor: Orionis Biosciences Inc

Sex: All

Age: 18+

Code: NCT06607939

Phase 1, Recruiting

Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

for
Advanced or Metastatic Solid Tumor, Liver Failure
Location: Newark DE, Baltimore MD, Houston TX, San Antonio TX
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT04617522

Phase 1, Recruiting

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing

for
Patients Undergoing Routine Health Care, Heart Diseases,
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT01280825

Recruiting

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

for
Metastatic Cancer, Oligoprogressive
Location: Montreal
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Sex: All

Age: 18+

Code: NCT04989725

Phase 2, Recruiting

BostonGene-Integrated Genomic Registry (BIGR)

for
Malignancy
Location: Waltham MA
Sponsor: BostonGene

Sex: All

Age: 18+

Code: NCT04991922

Recruiting

Tumor Related Epilepsy

for
Epilepsy, Cancer, Brain Neoplasm
Location: Bethesda MD
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Sex: All

Age: 8 - 70+

Code: NCT02639325

Recruiting

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

for
Malignant Neoplasm
Location: Fairfax VA, Houston TX, San Antonio TX
Sponsor: Tyligand Pharmaceuticals (Suzhou) Limited

Sex: All

Age: 18 - 70+

Code: NCT06385925

Phase 1, Phase 2, Recruiting

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

for
Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer,
Location: Nashville TN, Denver CO, Los Angeles CA
Sponsor: RasCal Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT04678648

Phase 1, Recruiting

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

for
NSCLC, HNSCC, Melanoma, Metastatic Cancer, Advanced Solid Tumor,
Location: Pittsburgh PA, Irvine CA
Sponsor: CJ Bioscience, Inc.

Sex: All

Age: 18+

Code: NCT05877430

Phase 1, Phase 2, Recruiting

A New Psychotherapy Intervention for Older Cancer Patients

for
Cancer
Location: New York NY
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 70+

Code: NCT04452825

Recruiting

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

for
Carcinomas (Including Squamous Cell and Adenocarcinoma),
Location: Stanford CA
Sponsor: Stanford University

Sex: All

Age: 18+

Code: NCT00349830

Recruiting

What is ovarian cancer?

Ovarian cancer begins in or near the ovaries. About 9 in 10 cases are epithelial, and most of those are high grade serous tumors that research now shows usually start in the fallopian tubes rather than the ovary. Rarer types begin in the egg cells or in hormone producing cells. It is hard to catch early. The ovaries sit deep in the pelvis, and early symptoms like bloating, pelvic or back pain, feeling full quickly, and urinary urgency are vague and common. The most frequent sign at diagnosis is abdominal swelling from fluid, which means the cancer is already advanced.

Treatment has changed. Surgery to remove as much tumor as possible, followed by platinum chemotherapy, is still the foundation. Since 2014 PARP inhibitor pills have been used to delay recurrence in BRCA mutated and similar tumors, and testing every patient for these mutations is now standard. In 2022 the first antibody drug conjugate for ovarian cancer was approved for platinum resistant disease, with full approval in 2024. Prevention has moved too. Because most cancers start in the tubes, removing only the fallopian tubes during other pelvic surgery is being tested as a way to prevent cancer without early menopause.

Ovarian cancer shares its inherited risk genes with breast, pancreatic, and prostate cancer. Our cancer treatment guide explains how targeted therapies work.

Types of ovarian cancer clinical trials

How is ovarian cancer diagnosed and tested?

Who can participate in ovarian cancer clinical trials?

The stages of ovarian cancer, and why they matter for trials

How to enroll in an ovarian cancer clinical trial